What 5 Analyst Ratings Have To Say About ResMed - ResMed (NYSE:RMD)

In the latest quarter, 5 analysts provided ratings for ResMed (NYSE:RMD), showcasing a mix of bullish and bearish perspectives.

The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.

	Somewhat Bullish	Indifferent
Total Ratings	2	3
Last 30D	0	1
1M Ago	0	1
2M Ago	0	0
3M Ago	2	1

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $256.6, a high estimate of $283.00, and a low estimate of $232.00. This upward trend is evident, with the current average reflecting a 1.96% increase from the previous average price target of $251.67.

Investigating Analyst Ratings: An Elaborate Study

The perception of ResMed by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.

Analyst	Analyst Firm	Action Taken	Rating	Current Price Target	Prior Price Target
Adam Maeder	Piper Sandler	Announces	Neutral	$252.00	-
Jonathan Block	Stifel	Announces	Hold	$250.00	-
Craig Wong-Pan	RBC Capital	Raises	Sector Perform	$232.00	$224.00
Brett Fishbin	Keybanc	Raises	Overweight	$266.00	$251.00
Joe Vruwink	Baird	Raises	Outperform	$283.00	$280.00

Key Insights:

Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to ResMed. This information provides a snapshot of how analysts perceive the current state of the company.
Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of ResMed compared to the broader market.
Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.

Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of ResMed's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.

Stay up to date on ResMed analyst ratings.

About ResMed

ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.

ResMed: Delving into Financials

Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.

Revenue Growth: ResMed's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 11.08%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.

Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 25.43%, the company showcases strong profitability and effective cost control.

Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 6.19%, the company showcases effective utilization of equity capital.

Return on Assets (ROA): ResMed's ROA excels beyond industry benchmarks, reaching 4.42%. This signifies efficient management of assets and strong financial health.

Debt Management: ResMed's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.16.

The Core of Analyst Ratings: What Every Investor Should Know

Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.

Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.

Which Stocks Are Analysts Recommending Now?

Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. Click here to stay ahead of the market.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

RMDResMed Inc

$195.80-%

Overview

Market News and Data brought to you by Benzinga APIs

To add Benzinga News as your preferred source on Google, click here.